Form 4: AbCellera Director Stephen Quake Granted Stock Options

AbCellera Biologics Inc. Director Stephen Quake was granted 194,932 share options with an exercise price of $3.47, vesting over three years.

Summary

• Stephen Quake, a Director at AbCellera Biologics Inc. (ABCL), was granted 194,932 share options.
• The options have an exercise price of $3.47 per share.
• The grant date for these options is December 1, 2025.
• The options expire on December 1, 2035.
• The shares subject to the option will vest annually in substantially equal installments over a three-year period.
• The first tranche of options will vest on December 1, 2026, contingent on Mr. Quake's continuous service to the company.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and a long-term view. It's a routine compensation event, not a major market mover, hence a moderate positive score.

Positives

• Grant of stock options to a director aligns management incentives with shareholder interests.
• The exercise price of $3.47 provides a clear benchmark for future stock performance.

Risks

• The vesting of options is subject to the reporting person's continuous service to the issuer.
• The value of the options is dependent on the future market price of AbCellera Biologics Inc. common shares exceeding the exercise price.

Future Outlook

The grant of long-term stock options suggests an expectation of future growth and value creation for AbCellera Biologics Inc. over the vesting and exercise period.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align interests with shareholders. This particular grant is standard practice for retaining and motivating key personnel.

Comparison to Industry Standards

• The use of stock options with a multi-year vesting schedule is a standard compensation practice in the biotech sector, similar to companies like Regeneron Pharmaceuticals or Amgen, which often use equity grants to incentivize long-term value creation.
• The Rule 10b5-1 plan indicates a pre-planned transaction, which is a common mechanism for insiders to manage their stock holdings while avoiding accusations of trading on material non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of director's interests with shareholder value creation; potential for future dilution if options are exercised, though this is standard for equity compensation.

Next Steps

• The director will continue to provide service to AbCellera Biologics Inc. to ensure vesting of the options.
• Future Form 4 filings will report any exercise or sale of these options.

Key Dates

Recommendation

This Form 4 reports a routine stock option grant to an existing director, Stephen Quake, as part of his compensation. While it aligns management incentives with shareholder interests, it does not present new information that would fundamentally alter the investment thesis for AbCellera Biologics Inc. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not provide a strong catalyst for a 'buy' or 'sell' decision.

Keywords

AbCellera Biologics, ABCL, Stephen Quake, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Rule 10b5-1